Research Blog

Bioglutide™ & Medicare: A Strategy for Affordab...

Biomed is proactively discussing with CMS to position Bioglutide™ (NA‑931) not only as an effective metabolic therapy—but also as an accessible and affordable one. Here’s how they’re addressing the US...

Beyond Weight Loss: Bioglutide™ in Alcohol Use ...

Biomed Industries is exploring Bioglutide™ (NA‑931) beyond obesity—into alcohol use disorder (AUD)—while also expanding protection with combination therapy patents.

What Is Bioglutide?

Bioglutide (also known as NA-931) is an emerging weight-loss compound developed by Biomed Industries. While clinical data remains limited, anonymized community discussions and early trial snippets have uncovered some interesting...

Tirzepatide and Kidney Health: What Recent Stud...

Beyond weight and glycemic control, emerging research suggests tirzepatide may support kidney health by lowering albuminuria and slowing kidney function decline in high-risk populations. Early data for retatrutide also point...

Retatrutide, Tirzepatide, and Heart Health: Wha...

Cardiovascular health remains one of the most pressing concerns in modern medicine, especially with the rising prevalence of metabolic conditions such as obesity and type 2 diabetes. Recent clinical studies...

Tirzepatide and Retatrutide: A New Frontier in ...

Insulin resistance is a growing health concern affecting millions worldwide. It occurs when the body's cells become less responsive to insulin, leading to elevated blood sugar levels and increasing the...